Alterity Therapeutics Ltd ADR ATHE

$3.37 +0.15 (4.66%)

Valuation

Market cap
58,366,000
Revenue TTM
$0
Net income TTM
$-15,880,000
PE ratio
0.00
Forward PE
—
Profit margin
0.00%
Debt to equity
0.00

Trading

Volume
21,800
Avg volume
16,570
Day's range
$3.22 – $3.46
Shares out
18,126,000
Stochastic %K
30%
Beta
0.27
Analysts
Strong Sell
Price target
$11.75

Price

Company profile

Alterity Therapeutics Limited is engages in research and development of Parkinsonian and neurodegenerative disorders, including Multiple System Atrophy (MSA) and Parkinson's disease. The company's lead drug candidate is ATH434, a small molecule drug candidate that has completed Phase II clinical trial for the treatment of Parkinson's disease. It is also developing ATH434-201, which is in Phase II clinical trial to tr...

Show more

Alterity Therapeutics Limited is engages in research and development of Parkinsonian and neurodegenerative disorders, including Multiple System Atrophy (MSA) and Parkinson's disease. The company's lead drug candidate is ATH434, a small molecule drug candidate that has completed Phase II clinical trial for the treatment of Parkinson's disease. It is also developing ATH434-201, which is in Phase II clinical trial to treat multiple system atrophy early stage; and ATH434-202 that is in Phase II clinical trial to treat multiple system atrophy, as well as bioMUSE, biomarkers of progression in multiple system atrophy. The company also operates drug discovery platform that generates patentable chemical compounds to treat the underlying pathology of neurological diseases. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. Alterity Therapeutics Limited was incorporated in 1997 and is based in Melbourne, Australia.

Industry
Biotechnology
Sector
Healthcare
Phone
61 3 9349 4906
Website
https://alteritytherapeutics.com
Address
500 Collins Street, Level 15, Melbourne, Australia

Latest news

Stocktwits

ButcherBillCutting Oct 6, 5:11 PM
$ATHE
0 replies
GA09 Oct 5, 7:58 PM
$ATHE Bought some more shares at these levels. The news today could trigger acceleration of the discussions the CEO has been talking about in the past few seminars and presentations. The stock is oversold. A closure on partnership or an acquisition will trigger a sharp rerate of the company at much higher prices.
0 replies
GA09 Oct 5, 2:30 PM
$ATHE The next piece of news has to be partnership or acquisition. This is the catalyst the markets are waiting for thus the significant low valuation.
0 replies
prismmarketview Oct 5, 2:24 PM
$ATHE New Phase 2 analyses for ATH434 (iron chaperone) in MSA. 50mg: 4.64-pt advantage vs placebo on 11-item UMSARS Part I at Week 52 after baseline-severity adjustment, ~52% slowing of functional decline (p=0.032). Company cites ~3x the 1.5-pt clinically meaningful threshold. CSF NfL biomarker predicted faster decline: +1,000 pg/mL baseline = ~0.9 extra points of worsening at 52 wks (p=0.033), which Alterity wants to use in future trials to adjust for baseline severity. 75mg: 2.81-pt benefit, not significant (p=0.179). Key caveats: primary MRI endpoint (substantia nigra iron change) was missed. The dentate nucleus iron-redistribution explanation is still a hypothesis. Adjusted, post-analysis result in a small Phase 2. Plans a Phase 3, no timeline or financing disclosed here. https://prismmarketview.com/alterity-reports-positive-ath434-data-in-multiple-system-atrophy-study/
0 replies
tommy_john Oct 5, 1:46 PM
$ATHE sell the news event. It’s all about money now. And share structure
0 replies
CoachKenny Oct 5, 11:45 AM
$ATHE Even better than we thought! Sell it for $100 a share and let’s move on!
0 replies
klingracing Oct 2, 6:44 PM
$ATHE They have been crushing this bigly. Would love to see them get their ass burned.
1 replies
GA09 Oct 2, 11:55 AM
$ATHE Slow bleed. Death by a thousand cuts. while we wait for the next important catalyst and that being a partnership arrangement or a buy-out. No partnership and we pull back and trade between $3 and $4 for 2 years. Strategic partnership rerates the stock to $500M (minimum) depending on the structure. CEO said they are looking at a dual track approach - investment from biotech funds and partnership with pharma. They also want to launch Phase 3 trial by/before the end of the year. Debating on whether to buy more shares at these levels given CEO stated pharma companies have shown a keen interest in 434 and that there is "distinct possibility" of a partnership before Phase 3 trial.
1 replies